Skip to main content

Nutra Pharma Corp.

corporate_fare Company Profile

Nutra Pharma Corp.

NPHC·OTC·Life Sciences·CIK 0001119643

Nutra Pharma Corp. is a biopharmaceutical company focused on developing drugs for autoimmune disorders, viral diseases, and pain. The company was incorporated in California on February 1, 2000, initially as Exotic-Bird.com, and has been conducting operations since October 2003. Nutra Pharma engages in drug discovery research and development, as well as the acquisition, licensing, and commercialization of pharmaceutical products and technologies. This includes homeopathic drugs, which are natural products with ingredients listed in the Homeopathic Pharmacopoeia of the United States (HPUS), and ethical drugs, which are licensed drugs that have received Federal Drug Administration (FDA) approval after extensive testing. Nutra Pharma has launched several consumer products. In October 2009, it introduced Cobroxin, an over-the-counter pain reliever for moderate to severe chronic pain. This was followed by Nyloxin in May 2010, a stronger over-the-counter pain reliever for severe chronic pain. The company expanded into the animal health market with Pet Pain-Away in December 2014, an over-the-counter pain reliever for cats and dogs, and Equine Pain-Away in October 2019, an over-the-counter topical pain reliever for horses. In March 2021, Nutra Pharma launched Luxury Feet, an over-the-counter pain reliever and anti-inflammatory product for women experiencing pain or discomfort from high heels. As of October 2021, the company also manufactures private-labeled products for third-party distributors. Nutra Pharma seeks strategic licensing partnerships to manage risks in drug development.

Nutra Pharma Corp. (OTC:NPHC) is a publicly traded company in the Life Sciences sector. Wiseek monitors NPHC SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Nutra Pharma Reports $4.4M Loss, Going Concern Warning, and $0 Cash

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$257.61K
Net Income
-$2.05M
Diluted EPS
$0.00
Op. Cash Flow
-$1.16M
Free Cash Flow
-$1.19M
Gross Profit
$196.63K
Operating Income
-$1.46M
Cash & Equivalents
$12.18K
Total Debt
$9.76M
Debt / Equity
-0.58×
Net Margin
-7.95×
Shares Outstanding
7.1B sh
Source: 10-K · filed 2026-05-20 · accession 0001493152-26-024641
$0.0001
52-week range · as of 2026-08-19 $0.000001 – $0.005
Market cap
$715.97K
Volume
50.3K (0.0× avg)
3-mo avg 1.1M
Live data · 2026-08-19 19:52 UTC · Market open

show_chartPrice Chart

Loading chart...

feed NPHC - Latest Insights

NPHC
Aug 19, 2026, 12:45 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0001
Real-time Price: $0.0001 info
Change: $0 (0%) info
Market Cap: $715.973K info